Meeder Asset Management Inc. acquired a new stake in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, Holdings Channel reports. The institutional investor acquired 1,574 shares of the biopharmaceutical company’s stock, valued at approximately $289,000.
Several other large investors have also recently added to or reduced their stakes in the stock. Security National Trust Co. purchased a new stake in Shire PLC during the second quarter valued at approximately $641,000. John G Ullman & Associates Inc. purchased a new stake in Shire PLC during the second quarter valued at approximately $1,495,000. Goelzer Investment Management Inc. purchased a new stake in Shire PLC during the second quarter valued at approximately $3,136,000. Kwmg LLC purchased a new stake in Shire PLC during the second quarter valued at approximately $244,000. Finally, Rothschild Investment Corp IL increased its stake in Shire PLC by 43.8% in the second quarter. Rothschild Investment Corp IL now owns 10,642 shares of the biopharmaceutical company’s stock valued at $1,959,000 after buying an additional 3,242 shares in the last quarter. Hedge funds and other institutional investors own 24.26% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.57% on Friday, hitting $203.05. The stock had a trading volume of 973,192 shares. The stock has a market cap of $60.48 billion, a PE ratio of 42.20 and a beta of 1.11. The stock has a 50 day moving average of $196.29 and a 200-day moving average of $184.42. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. The company earned $2.43 million during the quarter, compared to analysts’ expectations of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.63 EPS. Equities research analysts anticipate that Shire PLC will post $12.93 EPS for the current year.
The company also recently announced a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be paid a $0.139 dividend. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is presently 15.63%.
Several research firms have recently commented on SHPG. Jefferies Group restated a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a report on Tuesday, September 20th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Monday, September 19th. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a report on Tuesday, August 30th. TheStreet downgraded Shire PLC to a “hold” rating in a report on Thursday, August 4th. Finally, Zacks Investment Research upgraded Shire PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. Shire PLC has an average rating of “Buy” and an average price target of $230.67.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.